Cargando…

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells

(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vital, Patrik da Silva, Bonatelli, Murilo, Dias, Marina Pereira, de Salis, Larissa Vedovato Vilela, Pinto, Mariana Tomazini, Baltazar, Fátima, Maria-Engler, Silvya Stuchi, Pinheiro, Céline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779063/ https://www.ncbi.nlm.nih.gov/pubmed/36555289 http://dx.doi.org/10.3390/ijms232415650

Ejemplares similares

Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma
por: Siena, Ádamo Davi Diógenes, et al.
Publicado: (2022)

Redox-Related Proteins in Melanoma Progression
por: Carvalho, Larissa A. C., et al.
Publicado: (2022)

Apoptosis through Bcl-2/Bax and Cleaved Caspase Up-Regulation in Melanoma Treated by Boron Neutron Capture Therapy
por: Faião-Flores, Fernanda, et al.
Publicado: (2013)

Development of Epidermal Equivalent from Electrospun Synthetic Polymers for In Vitro Irritation/Corrosion Testing
por: Camarena, Denisse Esther Mallaupoma, et al.
Publicado: (2020)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Curcumin Analog DM-1 in Monotherapy or Combinatory Treatment with Dacarbazine as a Strategy to Inhibit In Vivo Melanoma Progression
por: Faião-Flores, Fernanda, et al.
Publicado: (2015)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Dual Effect of Serum Amyloid A on the Invasiveness of Glioma Cells
por: Knebel, Franciele Hinterholz, et al.
Publicado: (2013)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

3-Bromopyruvate as an Alternative Option for the Treatment of Protothecosis
por: Jagielski, Tomasz, et al.
Publicado: (2018)

The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors
por: Silva, Eduardo C.A., et al.
Publicado: (2018)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
por: Castellani, Elisa, et al.
Publicado: (2012)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

Transport of 3-bromopyruvate across the human erythrocyte membrane
por: Sadowska-Bartosz, Izabela, et al.
Publicado: (2014)

2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells
por: Franco, Ylana Adami, et al.
Publicado: (2023)

Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study
por: El Sayed, Salah Mohamed, et al.
Publicado: (2014)

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
por: Salton, Maayan, et al.
Publicado: (2015)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
por: Wolf, Sanne EJ, et al.
Publicado: (2013)

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
por: de Haan, Jorine, et al.
Publicado: (2018)

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib
por: Rajczykowski, Marcin, et al.
Publicado: (2018)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
por: Zhao, Kun, et al.
Publicado: (2020)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
por: Radi, Rakan, et al.
Publicado: (2022)

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells
por: Bokharaie, Honey, et al.
Publicado: (2022)

Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas
por: Liu, Fang, et al.
Publicado: (2013)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

Vemurafenib and cutaneous adverse events - report of five cases
por: Silva, Giselle de Barros, et al.
Publicado: (2015)

Construction and Evaluation of Folic Acid-Modified 3-Bromopyruvate Cubosomes
por: Hou, Fangyan, et al.
Publicado: (2020)

In vitro and in vivo effects of 3-bromopyruvate against Echinococcus metacestodes
por: Xin, Qi, et al.
Publicado: (2019)

Mitochondrial Function Are Disturbed in the Presence of the Anticancer Drug, 3-Bromopyruvate
por: Cal, Magdalena, et al.
Publicado: (2021)

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
por: Faião-Flores, F, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ucaloc7kqrf7nqkcp09j8n3cho